Skip to main content

Risankizumab Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 29, 2022.

For the Consumer

Applies to risankizumab: parenteral injection

Side effects include:

Common adverse effects (≥1%): Upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.

For Healthcare Professionals

Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution


Very common (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)

Common (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)[Ref]


Common (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)[Ref]


Very common (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (13%)[Ref]


Common (1% to 10%): Fatigue, asthenia[Ref]

Nervous system

Common (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)[Ref]


Uncommon (0.1% to 1%): Folliculitis, urticaria[Ref]

Frequently asked questions


1. "Product Information. Skyrizi (risankizumab)." AbbVie US LLC (2019):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.